PCOS Renamed To Expose Its Hidden Burden
2026-05-13
The old label “polycystic ovary syndrome” has always been misleading. It shrinks a systemic endocrine disorder into a gynecology problem, and it trains clinicians to stare at ovaries while the rest of the body absorbs the damage. A new name, focused on its androgen excess and metabolic disruption, is an explicit rebuke to that tunnel vision.
The uncomfortable truth is that fertility has functioned as medicine’s organizing principle for this condition. Ovulation induction, assisted reproduction and menstrual regulation have dominated treatment algorithms, even though hyperinsulinemia, dyslipidemia and chronic low‑grade inflammation drive much of the long‑term morbidity. Weight gain, insulin resistance and elevated blood pressure are not side notes; they are core pathophysiology.
Equally sidelined have been anxiety, depression and body‑image distress, which track closely with androgen excess, hirsutism and weight cycling. Yet diagnostic criteria still lean on ultrasound findings and cycle length, not on cardiometabolic risk scores or validated mental‑health screening tools. By reframing the disorder through its hormonal and metabolic signature, the new terminology pressures guidelines to integrate cardiovascular risk stratification, glucose tolerance testing and structured psychological care into standard management, rather than reserving serious attention only for patients trying to conceive.
Loading...
